BridgeBio Oncology Therapeutics, Inc.
Business
BridgeBio Oncology Therapeutics is a clinical-stage biotechnology company developing orally bioavailable small molecule inhibitors targeting RAS and PI3Kα oncogenic drivers in cancers including lung, breast, pancreas and colon. The company's pipeline consists of three programs: BBO-8520 (KRAS G12C ON/OFF inhibitor), BBO-11818 (pan-KRAS ON/OFF inhibitor), and BBO-10203 (RAS:PI3Kα Breaker), each in Phase 1 clinical trials. BridgeBio intends to commercialize its product candidates in the U.S. and potentially other regions through its own infrastructure and sales capabilities.
Summary from 10-K filed 2026-03-05
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|
| Research and development | 121 | 73 | — | |
| General and administrative | 25 | 8 | 41,692 | |
| Total operating expenses | 146 | 81 | — | |
| Loss from operations | −146 | −81 | −41,692 | |
| Interest income | 11 | 6 | — | |
| Income from transition services agreements | 1 | 775,000 | — | |
| Change in fair value of participation right liability | −725,000 | −564,000 | — | |
| Other income (expense) | −35,000 | 0 | — | |
| Total other income (expense), net | 12 | 7 | — | |
| Net loss | −134 | −74 | −41,692 | |
| Net loss per share attributable to common stockholders, basic | −4.3 | −5,756 | — | |
| Net loss per share attributable to common stockholders, diluted | −4.3 | −5,756 | — | |
| Weighted-average number of shares used in computing net loss per share attributable to common stockholders, basic | 31 | 12,903 | — | |
| Weighted-average number of shares used in computing net loss per share attributable to common stockholders, diluted | 31 | 12,903 | — |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|
| Cash and cash equivalents | 374 | 31 | — | — | |
| Short-term marketable securities | 52 | 125 | — | — | |
| Receivables from related parties | 386,000 | 81,000 | — | — | |
| Prepaid expense and other current assets | 7 | 3 | — | — | |
| Total current assets | 432 | 159 | — | — | |
| Property and equipment, net | 956,000 | 490,000 | — | — | |
| Operating lease right-of-use asset | 2 | 0 | — | — | |
| Other non-current assets | 13 | 5 | — | — | |
| Restricted cash | 132,000 | 132,000 | — | — | |
| Total assets | 448 | 164 | 332,894 | — | |
| Accounts payable | 1 | 3 | — | — | |
| Accrued compensation and benefits | 6 | 4 | — | — | |
| Accrued research and development liabilities | 26 | 8 | — | — | |
| Accrued professional services | 674,000 | 655,000 | — | — | |
| Payables to related parties | 534,000 | 483,000 | 70,095 | — | |
| Operating lease liability, current | 522,000 | 0 | — | — | |
| Other accrued liabilities | 240,000 | 166,000 | — | — | |
| Participation right liability | 0 | 3 | — | — | |
| Total current liabilities | 35 | 20 | 396,463 | — | |
| Operating lease liability, noncurrent | 2 | 0 | — | — | |
| Total liabilities | 37 | 20 | 396,463 | — | |
| Commitments and contingencies (Note 7) | — | — | — | — | |
| Common stock, $0.0001 par value; 500,000,000 and 41,341,250 shares authorized as of December 31, 2025 and December 31, 2024, respectively; 79,991,768 and 28,415 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | 8,000 | 0 | — | — | |
| Additional paid-in capital | 768 | 44 | 24,540 | — | |
| Accumulated deficit | −357 | −223 | −88,569 | — | |
| Accumulated other comprehensive income | 16,000 | 348,000 | — | — | |
| Total stockholders' equity (deficit) | 411 | −179 | −116 | −21,877 | |
| Total liabilities, redeemable convertible preferred stock, and stockholders' equity (deficit) | 448 | 164 | 332,894 | — |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|
| Depreciation of property and equipment | 300,000 | 200,000 | — | |
| Stock-based compensation | 6 | 4 | — | |
| Net accretion of premiums on marketable securities | −1 | −2 | — | |
| Amortization of right-of-use assets | 330,000 | 0 | — | |
| Prepaid expense and other currents assets | −3 | −1 | — | |
| Other non-current assets | −8 | −4 | — | |
| Accounts payble | −2 | 2 | — | |
| Accrued compensation and benefits | 2 | 3 | — | |
| Accrued research and development liabilities | 18 | 5 | — | |
| Accrued professional services | −102,000 | 518,000 | — | |
| Operating lease liabilities | −47,000 | 0 | — | |
| Other accrued liabilities | 74,000 | 141,000 | — | |
| Balances due to and from related parties | −254,000 | 9 | — | |
| Net cash used in operating activities | −114 | −55 | — | |
| Maturities of marketable securities | 158 | 32 | — | |
| Purchases of marketable securities | −84 | −154 | — | |
| Change in related party receivables related to cash pooling arrangement | 0 | 2 | — | |
| Purchases of property and equipment | −606,000 | −49,000 | — | |
| Net cash provided by (used in) investing activities | 73 | −121 | — | |
| Proceeds from reverse recapitalization and PIPE Financing | 373 | 0 | — | |
| Payment of deferred transaction costs | −12 | 0 | — | |
| Issuance of Series A redeemable convertible preferred stock | 0 | 6 | — | |
| Issuance of Series B redeemable convertible preferred stock, net of issuance costs | 22 | 199 | — | |
| Contribution from BridgeBio Pharma | 0 | 1 | — | |
| Exercise of common stock options for cash | 45,000 | 52,000 | — | |
| Net cash provided by financing activities | 383 | 206 | — | |
| Net increase in cash, cash equivalents, and restricted cash | 343 | 31 | — | |
| Settlement of participation right liability upon issuance of Series B redeemable convertible preferred stock | 4 | 0 | — | |
| Right-of-use asset recognized in exchange for operating lease liabilities | 3 | 0 | — | |
| Unpaid property and equipment included in accounts payable | 140,000 | 0 | — | |
| Deferred de-SPAC transaction costs included in accrued professional services | 123,000 | 0 | — | |
| Conversion of related party payables into Series A redeemable convertible preferred stock issued to BridgeBio Pharma | 0 | 20 | — | |
| Initial recognition of participation right liability in connection with issuance of Series B redeemable convertible preferred stock | 0 | 3 | — | |
| Non-cash transfers of property and equipment from BridgeBio Pharma | 0 | 54,000 | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is BridgeBio Oncology Therapeutics, Inc.'s CIK number?
BridgeBio Oncology Therapeutics, Inc.'s SEC CIK number is 0001869105 (1869105). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find BridgeBio Oncology Therapeutics, Inc.'s SEC filings?
All of BridgeBio Oncology Therapeutics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did BridgeBio Oncology Therapeutics, Inc. last report earnings?
BridgeBio Oncology Therapeutics, Inc. (BBOT) most recently filed an earnings 8-K with the SEC on May 12, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-219801). This is BridgeBio Oncology Therapeutics, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is BridgeBio Oncology Therapeutics, Inc.'s most recent earnings 8-K?
BridgeBio Oncology Therapeutics, Inc.'s latest earnings 8-K (Item 2.02) was filed May 12, 2026 under accession 0001193125-26-219801. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View BridgeBio Oncology Therapeutics, Inc.'s latest earnings 8-K →
Look up any company's CIK number →